Question 10081
Topic: Physiology & RehabilitationCorrect Answer & Explanation
. Loss of proprioception and vibration sensation
Practice Set 505 of 789
This practice set contains high-yield board review questions covering key concepts in 1. General Principles & Basic Science. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.
. Loss of proprioception and vibration sensation
A 7-year-old child with Osteogenesis Imperfecta Type IV has been on intravenous pamidronate therapy for 3 years. Which of the following radiographic findings is a direct consequence of this pharmacological treatment?
. Transverse sclerotic metaphyseal bands
A 15-year-old girl with Osteogenesis Imperfecta Type I presents with progressive hearing loss. What is the most common etiology of hearing impairment in patients with OI?
. Conductive hearing loss due to ossicular dislocation or fixation
In Osteogenesis Imperfecta, treatment with bisphosphonates reduces fracture frequency and increases bone mineral density. However, long-term use has been associated with which of the following orthopedic complications?
. Delayed healing of osteotomies
The medication Zolgensma (Onasemnogene abeparvovec) is an FDA-approved gene therapy for SMA. What is its mechanism of action?
. It utilizes an adeno-associated virus 9 (AAV9) vector to deliver a functional copy of the SMN1 gene.
A 10-year-old boy presents with forearm deformity and restricted pronosupination. Radiographs reveal calcification of the interosseous membrane and a history of hyperplastic callus formation following a previous femur fracture. Which genetic mutation is most likely responsible for this specific phenotype?
. IFITM5
A 3-year-old child with severe Osteogenesis Imperfecta is started on cyclical intravenous Pamidronate. Which of the following best describes the cellular mechanism of action of this medication?
. Inhibits osteoclast activity by disrupting the mevalonate pathway
. Decreased cortical thickness, decreased trabecular volume, and hypercellularity
. It delivers a fully functional copy of the human SMN1 gene via an AAV9 viral vector
A patient diagnosed with Osteogenesis Imperfecta Type VI is noted to have a paradoxically poor response to bisphosphonate therapy and exhibits an isolated mineralization defect on bone histology that mimics osteomalacia. Which gene is most likely mutated in this patient?
. SERPINF1
The Sofield-Millar operation remains a foundational concept in the surgical management of severe long bone deformities in Osteogenesis Imperfecta. What does this classic procedure fundamentally entail?
. Multiple sequential osteotomies of the diaphysis, realignment, and intramedullary rod fixation
. The primary and secondary dentition appear opalescent, yellow-brown, and wear rapidly; commonly associated with OI Types III and IV.
While bisphosphonates (antiresorptive agents) are the standard of care for severe Osteogenesis Imperfecta, recent research has explored anabolic agents to increase bone formation. Which of the following drugs represents an anabolic approach by acting as a monoclonal antibody against sclerostin?
. Romosozumab
A 14-year-old female with Osteogenesis Imperfecta has been treated with intravenous pamidronate for 10 years. Radiographs of her distal femur reveal multiple transverse radiodense lines.
What is the mechanism of action of this medication in producing these lines?

. Inhibition of farnesyl pyrophosphate synthase in osteoclasts
. Type V
A 16-year-old male with Osteogenesis Imperfecta Type VI presents with a femur fracture. He has a known SERPINF1 mutation. How does the pathophysiology and medical management of Type VI differ from classical OI (Types I-IV)?
. It features a mineralization defect resembling osteomalacia and responds poorly to bisphosphonates
A 15-year-old with severe OI has experienced multiple long bone fractures despite years of maximum-dose IV bisphosphonate therapy. The multidisciplinary team considers switching to Denosumab. What is the mechanism of action of Denosumab?
. Binds and neutralizes RANK ligand (RANKL), preventing osteoclast activation
. Inhibits osteoclast farnesyl pyrophosphate synthase
. It acts as a small molecule modifying pre-mRNA splicing of the SMN2 gene
. Presence of woven bone retaining primary trabeculae rather than mature lamellar bone